359.81
-1.54 (-0.43%)
| Previous Close | 361.35 |
| Open | 361.55 |
| Volume | 398,263 |
| Avg. Volume (3M) | 1,396,780 |
| Market Cap | 47,536,201,728 |
| Price / Earnings (TTM) | 1,240.73 |
| Price / Earnings (Forward) | 49.02 |
| Price / Sales | 14.82 |
| Price / Book | 202.20 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Profit Margin | -11.49% |
| Operating Margin (TTM) | 3.04% |
| Diluted EPS (TTM) | -2.11 |
| Quarterly Revenue Growth (YOY) | 20.20% |
| Total Debt/Equity (MRQ) | 2,358.25% |
| Current Ratio (MRQ) | 3.04 |
| Operating Cash Flow (TTM) | -45.11 M |
| Levered Free Cash Flow (TTM) | 223.09 M |
| Return on Assets (TTM) | -1.79% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Alnylam Pharmaceuticals, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.25 |
|
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 3.81% |
| % Held by Institutions | 97.56% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 530.00 (Truist Securities, 47.30%) | Buy |
| Median | 486.50 (35.21%) | |
| Low | 351.00 (Leerink Partners, -2.45%) | Hold |
| Average | 466.60 (29.68%) | |
| Total | 7 Buy, 3 Hold | |
| Avg. Price @ Call | 364.93 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 30 Jan 2026 | 462.00 (28.40%) | Buy | 338.06 |
| 12 Jan 2026 | 529.00 (47.02%) | Buy | 370.91 | |
| HC Wainwright & Co. | 30 Jan 2026 | 510.00 (41.74%) | Buy | 338.06 |
| Morgan Stanley | 30 Jan 2026 | 408.00 (13.39%) | Hold | 338.06 |
| Barclays | 28 Jan 2026 | 527.00 (46.47%) | Buy | 349.58 |
| RBC Capital | 20 Jan 2026 | 465.00 (29.23%) | Buy | 355.53 |
| Wells Fargo | 20 Jan 2026 | 376.00 (4.50%) | Hold | 355.53 |
| 11 Nov 2025 | 479.00 (33.12%) | Hold | 451.95 | |
| Needham | 12 Jan 2026 | 529.00 (47.02%) | Buy | 370.91 |
| Truist Securities | 08 Jan 2026 | 530.00 (47.30%) | Buy | 399.40 |
| Leerink Partners | 15 Dec 2025 | 351.00 (-2.45%) | Hold | 391.50 |
| Stifel | 11 Dec 2025 | 508.00 (41.18%) | Buy | 412.63 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 Jan 2026 | Announcement | Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results |
| 11 Jan 2026 | Announcement | Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact |
| 05 Jan 2026 | Announcement | Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference |
| 17 Dec 2025 | Announcement | Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics |
| 11 Dec 2025 | Announcement | Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027 |
| 03 Dec 2025 | Announcement | Alnylam Pharmaceuticals Announces Changes to Board of Directors |
| 08 Nov 2025 | Announcement | New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM |
| 04 Nov 2025 | Announcement | Alnylam to Webcast Presentations at Upcoming November Investor Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |